Clinical Trial

Role of Omega-DEK in Childhood Apraxia of Speech

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a 20-week study for children between 3 and 6 years old with confirmed childhood apraxia of speech (CAS). The study includes a 12-week open-label pilot feasibility study of an investigational drug (Omega-DEK) plus L-carnitine (Carnitor®), which is followed by an 8-week randomized, placebo-controlled discontinuation period among the same study participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-10.
Trial Details
NCT Number NCT07216001
Lead Sponsor Claudia R. Morris
Conditions Childhood Apraxia of Speech, Verbal Apraxia, Autism
Enrollment 34 participants
Start Date 2026-11
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29